Table 2.
Adaptive immune cells impacted by Chinese medicine compounds.
| Immune cells | Chinese medicine compounds | Signaling pathway/Cytokines | Specific main effects | Cancer types | Ref |
|---|---|---|---|---|---|
| CD4+ T lymphocytes | Yu-Ping-Feng | ↑IFN-γ/IL-4 ratio↑IL-12, TNF-α, IFN-γ; ↓IL-10, IL-5, IL-4 | ↓Th2-biased immune state | Hepatocellular carcinoma | (12) |
| ↑MHC II in Macrophages; ↑IL-2, IL-12; ↓TGF-β, IL-4 | ↑Th1 immune response; ↑The lysis capacity of CD4+T cells | Orthotopic lung cancer | (24) | ||
| ↑The proportion of CD4+T cells | Lewis lung cancer | (36) | |||
| Yangyin Wenyang | ↑TNF-α,IL-2,IFN-γ; ↑IFN-γ/IL-4 radio | ↑The differentiation of T cells into Th1; ↑The ratio of Th1/Th2 | Non-small cell lung cancer | (29) | |
| Quxie capsule | ↑Foxo1, T-bet | ↑The ratio of Th1/Th2 | Colorectal cancer | (44) | |
| Compound Sophorae Decoction | ↓STAT3, IL-17 | ↓The proportion of Th17 | UCRCC | (45) | |
| JC-001 | ↑IL-2, IL-10, TNF-α, IFN-γ; ↓TGF-β, IL-17A | ↑Th1 function; ↓Th17 function | Lewis lung cancer | (46) | |
| ↑T-bet, GATA-3 | ↑Th1 function; ↓Th17 function | Hepatocellular carcinoma | (47) | ||
| CD8+ T lymphocytes | Compound kushen injection | ↓Lag-3, PD-1, TIGIT,Tim-3; | ↓CD8+T cells exhaustion; | Hepatocellular carcinoma | (23) |
| ↑TNF-α, Perforin, IFN-γ, Granzyme-B | ↑CD8+T cells cytotoxicity | ||||
| Yangyin Wenyang | ↑MAPK, NF-κB signaling pathways | ↑CD8+T cells generation by mature DCs | Non-small cell lung cancer | (29) | |
| Tien-Hsien liquid | ↑IFN-γ, IL-2, TNF-α | ↑The number and cytotoxicity of CTLs | Colorectal Cancer | (33) | |
| Yu-Ping-Feng | ↑The proportion of CD8+T cells | Lewis lung cancer | (36) | ||
| JC-001 | ↑IL-12 p70, IFN-γ | ↑CD8+T cells generation | Lewis lung cancer | (46) | |
| Shugan Jianpi formula | ↓CD8+T cells apoptosis | Breast cancer | (48) | ||
| Xiao-Ai-Ping | ↑Perforin, IFN-γ, Granzyme-B | ↑CD8+T cells proliferation and function | Lewis lung cancer | (49) | |
| Shenqi Fuzheng Injection | ↓IL-10, TGF-β, VEGF | ↑The cytotoxic and migratory activities of Jurkat T cells | Melanoma | (50) | |
| Tregs | Quxie capsule | ↓Foxp3 induced by↑Foxo1 | ↓The proportion of Treg; ↓The ratio of Th17/Treg cells | Colorectal cancer | (44) |
| JC-001 | ↓Foxp3, RORγt | ↓Treg function | Hepatocellular carcinoma | (47) | |
| Feiyanning Decoction | ↓Foxp3 | ↓The number of Tregs | Lewis lung cancer | (51) | |
| Yi-Yi-Fu-Zi-Bai-Jiang-San | ↑IL-6, CCXL13, IL-10 | ↓Tregs activated by ETBF | Colorectal cancer | (52) | |
| Xihuang Pill | ↓PI3K/Akt/AP-1 signaling pathway | ↓The proliferation of Tregs; ↑The apoptosis of Tregs | Breast cancer | (53) | |
| Fuzheng Fangai | ↓IL-17, IL-23, IFN-γ, Foxp3, RORγt, SOCS3, JAK2, STAT3 | ↓The proportion of Th17 and Treg; Restore the balance of Th17/Treg | Lewis lung cancer | (54) |
↑, Up-regulated or enhanced; ↓, Down-regulated or inhibited.